Fulton Bank N.A. decreased its position in AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 14.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,015 shares of the company’s stock after selling 702 shares during the period. Fulton Bank N.A.’s holdings in AstraZeneca were worth $265,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of AZN. DB Wealth Management Group LLC acquired a new position in shares of AstraZeneca in the 1st quarter worth approximately $26,000. Parkside Financial Bank & Trust increased its holdings in shares of AstraZeneca by 4,875.0% in the first quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after buying an additional 390 shares in the last quarter. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of AstraZeneca during the 4th quarter valued at $27,000. Fairfield Bush & CO. acquired a new stake in shares of AstraZeneca during the 1st quarter valued at $28,000. Finally, Quent Capital LLC acquired a new position in shares of AstraZeneca in the 4th quarter worth $31,000. Institutional investors own 21.55% of the company’s stock.
AstraZeneca Stock Down 0.2 %
NASDAQ AZN opened at $58.05 on Monday. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 0.74. The company has a 50 day moving average price of $64.58 and a two-hundred day moving average price of $64.98. AstraZeneca PLC has a 12-month low of $53.63 and a 12-month high of $71.70.
AstraZeneca Cuts Dividend
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on AZN. Morgan Stanley downgraded AstraZeneca from an “overweight” rating to an “equal weight” rating in a report on Wednesday, September 7th. Danske assumed coverage on shares of AstraZeneca in a research note on Tuesday, May 24th. They set a “buy” rating for the company. TheStreet downgraded shares of AstraZeneca from a “b-” rating to a “c” rating in a research report on Tuesday, August 30th. Citigroup lifted their target price on shares of AstraZeneca from £105 ($126.87) to £130 ($157.08) in a research report on Tuesday, July 12th. Finally, Credit Suisse Group downgraded shares of AstraZeneca from an “outperform” rating to a “neutral” rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, AstraZeneca has an average rating of “Hold” and a consensus price target of $8,840.50.
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- Kroger’s is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.